lymphoma (NHL) (excluding chronic lymphocytic lymphoma [CLL], small lymphocytic lymphoma
[SLL], and mantle cell lymphoma [MCL]) who completed a prior ABT-199 study, or were active
and assigned to ABT-199 when the study was completed, may roll over into this extension
study. Subjects will receive ABT-199 during this study.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.